Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics - The ALLIANCE study

被引:259
作者
Koren, MJ
Hunninghake, DB
机构
[1] Jacksonville Ctr Clin Res, Jacksonville, FL 32216 USA
[2] Univ Minnesota, Minneapolis, MN USA
关键词
D O I
10.1016/j.jacc.2004.07.053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study sought to determine if an aggressive, focused low-density lipoprotein cholesterol (LDL-C)-lowering strategy was superior to usual care for coronary heart disease (CHD) patients enrolled in health maintenance organization or Veterans Administration settings. BACKGROUND Statin therapy benefits are well established. No prospective, randomized studies have tested strategies to optimize these benefits in a "real-world" setting. METHODS A total of 2,442 CHD patients with hyperlipidemia were randomized to either an aggressive treatment arm using atorvastatin or usual care and followed for 51.5 months on average. Atorvastatin-group patients were titrated to LDL-C goals of <80 mg/dl (2.1 mmol/l) or a maximum atorvastatin dose of 80 mg/day. Usual-care patients received any treatment deemed appropriate by their regular physicians. End point assessments were complete in 958 atorvastatin-group and 941 usual-care patients. Partial assessments occurred in 259 patients in the atorvastatin group and 284 patients in the usual care group who did not complete four years of study participation because of adverse events, withdrawn consent, or follow-up loss. The primary efficacy parameter was time to first cardiovascular event. RESULTS A total of 289 (23.7%) patients in the atorvastatin group compared with 333 (27.7%) patients in the usual care group experienced a primary outcome (hazard ratio, 0.83; 95% confidence interval 0.71 to 0.97, p = 0.02). This reduction in morbidity was largely due to fewer non-fatal myocardial infarctions (4.3% vs. 7.7%, p = 0.0002). Levels of LDL-C were reduced more (34.3% vs. 23.3%, p < 0.0001) and National Cholesterol Education Program goals (LDL-C <100 mg/dl) more likely met at end-of-study visits (72.4% vs. 40.0%) in patients receiving atorvastatin compared with those receiving usual care. CONCLUSIONS An aggressive, focused statin therapy management strategy outperformed usual care in health maintenance organization and Veterans Administration clinic patients with CHD. (C) 2004 by the American College of Cardiology Foundation.
引用
收藏
页码:1772 / 1779
页数:8
相关论文
共 21 条
  • [1] [Anonymous], HEART DIS STROK STAT
  • [2] Campeau L, 1997, NEW ENGL J MED, V336, P153
  • [3] Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    Cannon, CP
    Braunwald, E
    McCabe, CH
    Rader, DJ
    Rouleau, JL
    Belder, R
    Joyal, SV
    Hill, KA
    Pfeffer, MA
    Skene, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1495 - 1504
  • [4] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [5] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [6] Cooper R, 2000, CIRCULATION, V102, P3137
  • [7] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS
    Downs, JR
    Clearfield, M
    Weis, S
    Whitney, E
    Shapiro, DR
    Beere, PA
    Langendorfer, A
    Stein, EA
    Kruyer, W
    Gotto, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20): : 1615 - 1622
  • [8] Fox KM, 2003, LANCET, V362, P782
  • [9] Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) -: Rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease
    Isaacsohn, JL
    Davidson, MH
    Hunninghake, D
    Singer, R
    McLain, R
    Black, DM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (02) : 250 - 252
  • [10] A CLINICAL-TRIAL OF THE ANGIOTENSIN-CONVERTING-ENZYME INHIBITOR TRANDOLAPRIL IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION
    KOBER, L
    TORPPEDERSEN, C
    CARLSEN, JE
    BAGGER, H
    ELIASEN, P
    LYNGBORG, K
    VIDEBEK, J
    COLE, DS
    AUCLERT, L
    PAULY, NC
    ALIOT, E
    PERSSON, S
    CAMM, AJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) : 1670 - 1676